Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2011 10:00 ET | Source: Hemispherx Biopharma, Inc.

FDA Authorizes Alferon LDO Clinical Study for Treatment and Prevention of Influenza

PHILADELPHIA, Jan. 4, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced today that the Food and Drug Administration (FDA) has lifted a...
December 28, 2010 16:56 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. to Restate 2009 Financial Statements

PHILADELPHIA, Dec. 28, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its intention to restate its financial statements in its Annual Report on Form 10-K for the year...
December 20, 2010 11:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Licenses Alferon N Injection(R) to GP Pharm in Latin America

PHILADELPHIA, Dec. 20, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that the Company has entered into an agreement with GP Pharm...
December 14, 2010 10:00 ET | Source: Hemispherx Biopharma, Inc.

FDA Grants Hemispherx Biopharma Extension in Its Pending NDA for Treatment of Chronic Fatigue Syndrome (CFS)

PHILADELPHIA, Dec. 14, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced today that the Food and Drug Administration (FDA) granted a 12...
December 09, 2010 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Extends GP Pharm License to Mexico for Ampligen to Treat for Chronic Fatigue Syndrome in Latin America

PHILADELPHIA, Dec. 9, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that the Company has amended its June 15, 2010 agreement with GP...
November 29, 2010 09:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Files With the FDA a Request to Maintain as Active Hemispherx NDA for Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS)

PHILADELPHIA, Nov. 29, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"), announced that the Company has requested an extension of time in which to...
November 22, 2010 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Publishes New Data on Ampligen(R)'s Activity in Chronic Fatigue Syndrome (CFS)

PHILADELPHIA, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced the publication of a peer-reviewed article providing new data on Ampligen®...
November 16, 2010 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. to Present at the 4th Annual Maxim Group Growth Conference

PHILADELPHIA, Nov. 16, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), an advanced specialty pharmaceutical company engaged in the clinical development of new drug...
November 11, 2010 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. to Discuss Third Quarter Results of Operations on Tuesday, November 16, 2010

PHILADELPHIA, Nov. 11, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), an advanced specialty pharmaceutical company engaged in the clinical development of new drug...
November 10, 2010 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Receives Therapeutic Discovery Project Grant From U.S. Department of Treasury

PHILADELPHIA, Nov. 10, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced today grant awards totaling $488,958 from the U.S. Department of Treasury in support of its...